# Margarita Majem

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/margarita-majem/

## Facts

| Field | Value |
| --- | --- |
| Citations | 24,725 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 57 |
| i10-index | 163 |
| Last Known Institution | Hospital de Sant Pau |
| OpenAlex ID | https://openalex.org/A5059355812 |
| ORCID iD | https://orcid.org/0000-0002-9919-7485 |
| Works | 570 |

## Researcher papers

- [Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial](https://scholariq.org/papers/pembrolizumab-versus-docetaxel-for-previously-treated-pd-l1-positive-advanced/)
- [Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-resected-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer](https://scholariq.org/papers/perioperative-pembrolizumab-for-early-stage-non-small-cell-lung-cancer/)
- [Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study](https://scholariq.org/papers/osimertinib-for-pretreated-egfr-thr790met-positive-advanced-non-small-cell-lung/)
- [Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC](https://scholariq.org/papers/overall-survival-with-osimertinib-in-resected-i-egfr-i-mutated-nsclc/)
- [Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer](https://scholariq.org/papers/tarlatamab-for-patients-with-previously-treated-small-cell-lung-cancer/)
- [Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial](https://scholariq.org/papers/adjuvant-osimertinib-for-resected-egfr-mutated-stage-ib-iiia-non-small-cell-lung/)
- [Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 Insertions](https://scholariq.org/papers/amivantamab-plus-chemotherapy-in-nsclc-with-i-egfr-i-exon-20-insertions/)
- [Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study](https://scholariq.org/papers/mechanisms-of-acquired-resistance-to-first-line-osimertinib-preliminary-data/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Hospital de Sant Pau](https://scholariq.org/institutions/hospital-de-sant-pau/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.